NHS (Neuberger Berman High Yield Strategies Fund) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NHS Neuberger Berman High Yield Strategies Fund Inc NHS
44 GF Score
Price $6.21
GF Value $7.23
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neuberger Berman High Yield Strategies Fund Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Neuberger Berman High Yield Strategies Fund is: No Data: Cannot be evaluated.

Neuberger Berman High Yield Strategies Fund  (AMEX:NHS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Neuberger Berman High Yield Strategies Fund Risk Assessment Related Terms

NHS vs NRO, TPVG, OPP: Risk Assessment Comparison

For the Asset Management subindustry, Neuberger Berman High Yield Strategies Fund's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuberger Berman High Yield Strategies Fund Risk Assessment vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Neuberger Berman High Yield Strategies Fund's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Neuberger Berman High Yield Strategies Fund's Risk Assessment falls into.


NHS
44GF Score
Neuberger Berman High Yield Strategies Fund Inc NHS
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuberger Berman High Yield Strategies Fund (NHS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuberger Berman High Yield Strategies Fund stock appears to be undervalued. The current stock price of $6.21 is trading 14.1% below its estimated GF Value™ of $7.23. GuruFocus considers Neuberger Berman High Yield Strategies Fund to be Modestly Undervalued.

Key valuation signals for NHS:

  • Risk Assessment:
  • GF Value™: $7.23 vs. price of $6.21 (14.1% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the NHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuberger Berman High Yield Strategies Fund Business Description

Address c/o Neuberger Berman Investment Advisers LLC, 1290 Avenue of the Americas, New York, NY, USA, 10104-0002
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
44GF Score

Get the complete analysis for NHS

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.21
Price
$7.23
GF Value